EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Tecan Group AG (TECN) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Tecan Group AG CHF 95.99, price CHF 218, upside -55.9%, quality 59 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · CH · ISIN CH0012100191

TG Some data Sep 24, 2026

Tecan Group AG

TECN · SW

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value CHF 95.99 · Strongly overvalued (−56%)
!Quality 59/100
!Weak Growth (revenue 5y +3.8 %/yr)
!Loss-making · -12.5% net margin (TTM)
✓Low debt · generates free cash flow
·0.69% dividend yield
!Trails peers (1/14)
!Narrow moat 24/100
!Insider activity 45/100
!Evidence only medium, so the estimate is less certain
!Weak on dividend: 14 out of 100

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

CHF 574.26 CHF 113.47 Fair Value CHF 95.99 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range CHF 113.47 – CHF 574.26 · fair‑value band CHF 70.51 – CHF 121.48 · the CHF 217.80 price screens above the CHF 95.99 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Tecan Group in your weekly email

Every Wednesday you see whether Tecan Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Tecan Group AG provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally. It operates in two segments: Life Sciences Business and Partnering Business.

Show more

Tecan Group AG provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally. It operates in two segments: Life Sciences Business and Partnering Business. The company offers liquid handling and automation, microplate readers and washers, software, consumables, sequencing reagents, immunoassays and antibodies, and Tecan Labwerx, an end-to-end automation solution. It also provides PARAMIT, a contract design and manufacturing service. Tecan Group AG has a strategic collaboration with NVIDIA Corporation to develop AI-enabled platform for data-driven laboratories to help discoveries and lab productivity. The company was founded in 1980 and is headquartered in Männedorf, Switzerland.

Stock analysis

Tecan Group AG (TECN) currently trades at CHF 217.80, while our model-based Fair Value estimate is CHF 95.99, implying the stock looks roughly 126.9% overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of CHF 125.65 per share, and 0 of the 15 models we run sit above the CHF 217.80 price.

Bear case: the Earnings-Based group reads lowest at CHF 29.32, and 15 of the 15 models stay below the price. Evidence for this calculation is medium.

Scenario range: CHF 70.51 (bear) to CHF 121.48 (bull), the price of CHF 217.80 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Tecan Group AG reported revenue of CHF 882M in FY2025 versus CHF 947M in FY2021, a compound −1.7%/yr. Reported net income was −CHF 111M in FY2025.

Key figures

Market cap CHF 2.8B · P/S ratio 2.58 · EPS (TTM) CHF −8.75 · Dividend yield 0.7% · Net margin −12.5% · Return on equity −8.6% · Return on assets (EBIT) 5.3% · Operating margin 4.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).

What moves the price

The share trades at its 52-week high and 92% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at −56%, TECN screens richer than that median.

Fair Value models

Bear CHF 70.51 Fair Value CHF 95.99 Bull CHF 121.48
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF CHF 94.76 CHF 140.91 CHF 207.40 78
Growth DCF CHF 96.31 CHF 137.33 CHF 193.03 76
EPV CHF 25.60 CHF 29.32 CHF 32.53 74
All 15 models by family
DCF Models
FCF DCF CHF 94.76 CHF 140.91 CHF 207.40 78
5Y Revenue Exit CHF 54.17 CHF 73.42 CHF 96.51 71
5Y EBITDA Exit CHF 84.01 CHF 128.57 CHF 179.45 73
10Y Revenue Exit CHF 67.78 CHF 88.45 CHF 113.71 66
10Y EBITDA Exit CHF 87.17 CHF 125.65 CHF 174.91 66
Earnings-Based
EPV CHF 25.60 CHF 29.32 CHF 32.53 74
Dividend Discount
Gordon GGM CHF 26.39 CHF 52.58 CHF 79.63 64
DDM Multi-Stage CHF 26.39 CHF 41.80 CHF 55.51 64
Multiples
EV/EBIT CHF 44.55 CHF 58.71 CHF 72.87 66
EV/EBITDA CHF 87.65 CHF 116.18 CHF 144.71 67
EV/Revenue CHF 32.38 CHF 45.38 CHF 58.37 54
Asset-Based
NCAV (Graham) CHF 45.49 CHF 60.96 CHF 90.98 54
Growth DCF
Growth DCF CHF 96.31 CHF 137.33 CHF 193.03 76
Rev-Margin DCF CHF 54.17 CHF 74.79 CHF 98.66 71
Economic Profit
ROIC Compounder CHF 25.60 CHF 29.32 CHF 32.53 70

Open the full fair value analysis →

Notify me when TECN reaches fair value

Put TECN on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 59/100

Of which business quality 59 · Market factors (momentum, volatility) 76

Profitability 13
Margins and returns on capital today
Quality Growth 30
Are margins and returns improving?
Cashflow 60
Earnings quality: real cash, not paper profit
Fin. Strength 86
Balance sheet, leverage, solvency risk
Investment 96
Disciplined investing over empire-building
Low Volatility 53
Calm price path (market factor)
Momentum 85
Price trend over the last 3–12 months (market factor)
52W Momentum 88
Distance to the 52-week high (market factor)
Net Issuance 88
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 37/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−5.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.8%
Start year 2020 (pandemic). Over 10 years: +7.2% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
16.8% (2020) → 4.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+13.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.7%
Yearly sales growth analysts expect, extended to five years.
After inflation (Switzerland: IMF forecast 0.6% a year to 2030, 0.8% from 2016 to 2025) that is about +13.1% a year for the price and +3.1% for the forecasts.
Forecast 2026 (sales)+0.1%
Forecast 2027 (sales)+5.2%
Projected 2028 (sales)+4.8%
Projected 2029 (sales)+4.4%
Projected 2030 (sales)+4.0%

TECN screens 127% overvalued. Compare with Intuitive Surgical, Inc →

Compare Tecan Group AG with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 203 stocks

Beats the industry median on 1/13 measures
Overall it trails its industry peers.
Valuation
Quality Score 59 · Above median
Fair Value upside −56% · Bottom 25%
Profitability
Return on assets 1% · Below median
Net margin (TTM) −13% · Bottom 25%
Operating margin (TTM) 5% · Below median
Growth and dividend
Revenue growth −5% · Bottom 25%
Dividend yield (TTM) 0.7% · Bottom 25%
Balance sheet
Debt / equity 0.13× · Above median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 2.90× · Pricier than median
P/S (TTM) 3.79× · Pricier than median
P/FCF 32.6× · Priciest 25%
EV/EBITDA 41.0× · Priciest 25%
PEG 1.71× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 15
FUTURE (revenue growth)0 · sector 31
PAST (return on equity)0 · sector 25
HEALTH (low debt)93 · sector 96
DIVIDEND (yield)14 · sector 33

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Intuitive Surgical, Inc ISRG $402.09 $353.38 −12%
EssilorLuxottica Société anonyme EL €144.50 €158.95 +10%
Medline Inc MDLN $34.43 $30.15 −12%
Becton, Dickinson and Company BDX $183.00 $103.53 −43%
Alcon Inc ALC $65.59 $39.78 −39%
ResMed Inc RMD A$31.61 A$34.77 +10%
West Pharmaceutical Services, Inc WST $371.09 $137.28 −63%
Sartorius Stedim Biotech S.A DIM €206.40 €54.82 −73%
Straumann Holding STMN CHF 97.86 CHF 45.50 −54%
Solventum Corporation SOLV $88.75 $130.51 +47%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Tecan Group AG Fair Value". https://www.fairvalue-calculator.com/stock/TECN

Frequently asked questions

Is Tecan Group AG (TECN) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of CHF 95.99 versus a price of CHF 217.80, about −56% upside (overvalued).
What is the fair value of TECN?
Our model-based fair value for Tecan Group AG is CHF 95.99 (as of Sep 24, 2026), built from audited fundamentals. The current price: CHF 217.80.
What is the quality score of TECN?
Tecan Group AG has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Tecan Group AG (TECN)?
Our model-based price target is the fair value of CHF 95.99 (as of Sep 24, 2026) from 15 valuation models. Cautious scenario CHF 70.51, optimistic scenario CHF 121.48. It is a calculation from audited fundamentals, not an analyst target.
What is the Tecan Group AG stock forecast for 2026?
Our models put fair value at CHF 95.99, about −56% upside versus a price of CHF 217.80 (overvalued). Cautious scenario CHF 70.51, optimistic scenario CHF 121.48. The calculation is refreshed regularly with new filings.
What is the revenue of Tecan Group AG (TECN)?
Tecan Group AG reported trailing-twelve-month revenue of about CHF 882M (latest available figure, as of Sep 24, 2026).
Does Tecan Group AG pay a dividend?
Tecan Group AG currently shows a dividend yield of about 0.69% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Tecan Group AG (TECN)?
For today's price to be fair in a discounted-cash-flow model, Tecan Group AG would have to grow free cash flow by +13.8 % per year for five years (discount rate 9.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +3.8 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of TECN use?
Our models discount Tecan Group AG at 9.7 %: a base by market capitalisation (mid), damped by beta 1.07, country premium for Switzerland. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Tecan Group AG that is +13.8 % per year a year over ten years, using the same discount rate (9.7 %) and the same formula as our fair value.
How much growth has Tecan Group AG (TECN) delivered so far?
Over the past 5 years revenue at Tecan Group AG grew +3.8 % a year. The price currently implies +13.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Tecan Group AG (TECN) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Tecan Group AG (+13.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Tecan Group AG (TECN)?
The free-cash-flow yield on the price is 3.72 %: that much free cash flow Tecan Group AG produces per unit of market value. When it exceeds the discount rate of our models (9.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Tecan Group AG (TECN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tecan Group AG it is CHF 95.99 per share (as of Sep 24, 2026), against a price of CHF 217.80. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Tecan Group AG stock overvalued or undervalued in 2026?
As of Sep 24, 2026, TECN trades above its calculated fair value: price CHF 217.80, fair value CHF 95.99, a gap of about −56% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TECN?
No. The price is what the market pays today (CHF 217.80); the fair value is what the company's own numbers justify (CHF 95.99). For Tecan Group AG the two are CHF 121.81 per share apart. That gap is exactly why we show both numbers side by side.
How much is Tecan Group AG worth?
The market values Tecan Group AG at about CHF 2.8B (market capitalisation, as of Sep 24, 2026). Per share that is CHF 217.80; our models calculate a fair value of CHF 95.99 per share.
What do the bullish and bearish scenarios say about TECN?
Our models span a range for Tecan Group AG: cautious scenario CHF 70.51, base CHF 95.99, optimistic CHF 121.48 per share (as of Sep 24, 2026, price CHF 217.80). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of TECN?
The PEG ratio of Tecan Group AG is 1.71 (P/E divided by earnings growth, as of Sep 24, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Tecan Group AG (TECN)?
Balance-sheet figures for Tecan Group AG (as of Sep 24, 2026): return on equity −8.6%, debt of 0.13 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is TECN from its 52-week high?
Tecan Group AG trades at CHF 217.80, at its 52-week high of CHF 218.80 and 92% above the low of CHF 113.47 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of CHF 95.99 is for.
Which stocks are comparable to Tecan Group AG?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Tecan Group AG stock attractive at the current price?
The data as of Sep 24, 2026: price CHF 217.80, calculated fair value CHF 95.99 (−56%), Quality Score 59/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TECN calculated?
We run Tecan Group AG through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of CHF 95.99, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Tecan Group AG itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Tecan Group AG (TECN)?
The closing price on Sep 23, 2026 was CHF 217.80. Our model-based fair value is CHF 95.99, about −56% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Tecan Group AG right now?
The price sits above even our optimistic bull case (CHF 121.48). The favourable scenario is already priced in. Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Tecan Group AG (TECN) come from?
Earnings per share at Tecan Group AG grew +7.0 % a year from 2014 to 2025. Broken into its drivers: revenue per share +8.6 %, EBIT margin −3.6 %, tax rate +1.3 %, residual (interest, one-offs) +0.8 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Tecan Group AG

How large is the market capitalisation of Tecan Group AG (TECN)?
The market capitalisation of Tecan Group AG is CHF 2.8B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Tecan Group AG (TECN)?
The price-to-sales ratio of Tecan Group AG is 2.58 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Tecan Group AG (TECN)?
Earnings per share at Tecan Group AG are CHF −8.75. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Tecan Group AG (TECN)?
The dividend yield of Tecan Group AG is 0.7%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Tecan Group AG (TECN)?
The net margin of Tecan Group AG is −12.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Tecan Group AG (TECN)?
The return on equity (ROE) of Tecan Group AG is −8.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Tecan Group AG (TECN)?
On an EBIT basis the return on assets of Tecan Group AG is 5.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Tecan Group AG (TECN)?
The operating margin of Tecan Group AG is 4.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Tecan Group AG (TECN)?
Revenue at Tecan Group AG is growing −5.2% versus a year earlier (3y avg −8.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Tecan Group AG (TECN)?
Earnings per share at Tecan Group AG are growing −19.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Tecan Group AG (TECN) carry?
The net debt of Tecan Group AG is CHF 42.0M (fiscal year 2025, ≈ 0.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Tecan Group AG in the live analysis

One click puts Tecan Group AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.